

<!DOCTYPE html>
<html lang="zh-CN" >



<head>
  <meta charset="UTF-8">

  <link rel="apple-touch-icon" sizes="76x76" href="/img/Logo.png">
  <link rel="icon" href="/img/Logo.png">
  

  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0, shrink-to-fit=no">
  <meta http-equiv="x-ua-compatible" content="ie=edge">
  
  <meta name="theme-color" content="#2f4154">
  <meta name="author" content="向海">
  <meta name="keywords" content="">
  
    <meta name="description" content="Different drug receptors">
<meta property="og:type" content="article">
<meta property="og:title" content="L4 Drug Receptors &amp; Pharmacodynamics">
<meta property="og:url" content="https://zhenyumi.github.io/posts/c9f809bd/index.html">
<meta property="og:site_name" content="鹘横海">
<meta property="og:description" content="Different drug receptors">
<meta property="og:locale" content="zh_CN">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202237756.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202626609.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202659615.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202826694.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202959083.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203134943.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203257458.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203332282.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203340234.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203730998.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315204050913.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315204328898.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315204857526.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205123930.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205156808.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205257899.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205318537.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205620730.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205641227.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315214914472.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315215630602.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315220126347.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315220248986.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315220309971.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315221048117.png">
<meta property="article:published_time" content="2021-04-16T06:03:04.000Z">
<meta property="article:modified_time" content="2021-04-16T06:03:04.000Z">
<meta property="article:author" content="向海">
<meta property="article:tag" content="Molecular Pharmacology">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202237756.png">
  
  
  
  <title>L4 Drug Receptors &amp; Pharmacodynamics - 鹘横海</title>

  <link  rel="stylesheet" href="https://lib.baomitu.com/twitter-bootstrap/4.6.1/css/bootstrap.min.css" />



  <link  rel="stylesheet" href="https://lib.baomitu.com/github-markdown-css/4.0.0/github-markdown.min.css" />

  <link  rel="stylesheet" href="https://lib.baomitu.com/hint.css/2.7.0/hint.min.css" />

  <link  rel="stylesheet" href="https://lib.baomitu.com/fancybox/3.5.7/jquery.fancybox.min.css" />



<!-- 主题依赖的图标库，不要自行修改 -->
<!-- Do not modify the link that theme dependent icons -->

<link rel="stylesheet" href="//at.alicdn.com/t/c/font_1749284_5i9bdhy70f8.css">



<link rel="stylesheet" href="//at.alicdn.com/t/c/font_1736178_k526ubmyhba.css">


<link  rel="stylesheet" href="/css/main.css" />


  <link id="highlight-css" rel="stylesheet" href="/css/highlight.css" />
  




  <script id="fluid-configs">
    var Fluid = window.Fluid || {};
    Fluid.ctx = Object.assign({}, Fluid.ctx)
    var CONFIG = {"hostname":"zhenyumi.github.io","root":"/","version":"1.9.8","typing":{"enable":true,"typeSpeed":70,"cursorChar":"_","loop":false,"scope":["home"]},"anchorjs":{"enable":true,"element":"h1,h2,h3,h4,h5,h6","placement":"left","visible":"hover","icon":""},"progressbar":{"enable":true,"height_px":3,"color":"#29d","options":{"showSpinner":false,"trickleSpeed":100}},"code_language":{"enable":true,"default":"TEXT"},"copy_btn":true,"image_caption":{"enable":true},"image_zoom":{"enable":true,"img_url_replace":["",""]},"toc":{"enable":true,"placement":"right","headingSelector":"h1,h2,h3,h4,h5,h6","collapseDepth":0},"lazyload":{"enable":true,"loading_img":"/img/loading.gif","onlypost":false,"offset_factor":2},"web_analytics":{"enable":false,"follow_dnt":true,"baidu":null,"google":{"measurement_id":null},"tencent":{"sid":null,"cid":null},"leancloud":{"app_id":null,"app_key":null,"server_url":null,"path":"window.location.pathname","ignore_local":false},"umami":{"src":null,"website_id":null,"domains":null,"start_time":"2024-01-01T00:00:00.000Z","token":null,"api_server":null}},"search_path":"/local-search.xml","include_content_in_search":true};

    if (CONFIG.web_analytics.follow_dnt) {
      var dntVal = navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack;
      Fluid.ctx.dnt = dntVal && (dntVal.startsWith('1') || dntVal.startsWith('yes') || dntVal.startsWith('on'));
    }
  </script>
  <script  src="/js/utils.js" ></script>
  <script  src="/js/color-schema.js" ></script>
  


  
<meta name="generator" content="Hexo 7.0.0"></head>


<body>
  

  <header>
    

<div class="header-inner" style="height: 70vh;">
  <nav id="navbar" class="navbar fixed-top  navbar-expand-lg navbar-dark scrolling-navbar">
  <div class="container">
    <a class="navbar-brand" href="/">
      <strong>鹘横海</strong>
    </a>

    <button id="navbar-toggler-btn" class="navbar-toggler" type="button" data-toggle="collapse"
            data-target="#navbarSupportedContent"
            aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
      <div class="animated-icon"><span></span><span></span><span></span></div>
    </button>

    <!-- Collapsible content -->
    <div class="collapse navbar-collapse" id="navbarSupportedContent">
      <ul class="navbar-nav ml-auto text-center">
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/" target="_self">
                <i class="iconfont icon-home-fill"></i>
                <span>首页</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/archives/" target="_self">
                <i class="iconfont icon-archive-fill"></i>
                <span>归档</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/categories/" target="_self">
                <i class="iconfont icon-category-fill"></i>
                <span>分类</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/tags/" target="_self">
                <i class="iconfont icon-tags-fill"></i>
                <span>标签</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/about/" target="_self">
                <i class="iconfont icon-user-fill"></i>
                <span>关于</span>
              </a>
            </li>
          
        
        
          <li class="nav-item" id="search-btn">
            <a class="nav-link" target="_self" href="javascript:;" data-toggle="modal" data-target="#modalSearch" aria-label="Search">
              <i class="iconfont icon-search"></i>
            </a>
          </li>
          
        
        
      </ul>
    </div>
  </div>
</nav>

  

<div id="banner" class="banner" parallax=true
     style="background: url('https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/Fluid/post/post2.jpg') no-repeat center center; background-size: cover;">
  <div class="full-bg-img">
    <div class="mask flex-center" style="background-color: rgba(0, 0, 0, 0.3)">
      <div class="banner-text text-center fade-in-up">
        <div class="h2">
          
            <span id="subtitle">L4 Drug Receptors & Pharmacodynamics</span>
          
        </div>

        
          
  <div class="mt-3">
    
    
      <span class="post-meta">
        <i class="iconfont icon-date-fill" aria-hidden="true"></i>
        <time datetime="2021-04-16 14:03" pubdate>
          2021年4月16日 下午
        </time>
      </span>
    
  </div>

  <div class="mt-1">
    
      <span class="post-meta mr-2">
        <i class="iconfont icon-chart"></i>
        
          306 字
        
      </span>
    

    
      <span class="post-meta mr-2">
        <i class="iconfont icon-clock-fill"></i>
        
        
        
          3 分钟
        
      </span>
    

    
    
  </div>


        
      </div>

      
    </div>
  </div>
</div>

</div>

  </header>

  <main>
    
      

<div class="container-fluid nopadding-x">
  <div class="row nomargin-x">
    <div class="side-col d-none d-lg-block col-lg-2">
      

    </div>

    <div class="col-lg-8 nopadding-x-md">
      <div class="container nopadding-x-md" id="board-ctn">
        <div id="board">
          <article class="post-content mx-auto">
            <h1 id="seo-header">L4 Drug Receptors &amp; Pharmacodynamics</h1>
            
            
              <div class="markdown-body">
                
                <p><strong>Pharmacology</strong></p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202237756.png" srcset="/img/loading.gif" lazyload alt="image-20210315202237756" style="zoom:100%;" />

<ul>
<li>Processes of drug action that occur when drug reaches site of action and produces an effect.</li>
</ul>
<h2 id="Pharmocodynamic-Phase"><a href="#Pharmocodynamic-Phase" class="headerlink" title="Pharmocodynamic Phase"></a>Pharmocodynamic Phase</h2><p>Action vs. Effect</p>
<ul>
<li>action &#x3D; how the drug works<ul>
<li>usually by enhancing or inhibiting cell function</li>
</ul>
</li>
<li>effect &#x3D; consequence of drug action on body</li>
</ul>
<p>Example: Aspirin</p>
<ul>
<li>action: block prostaglandin Synthesis， via binding and inhibiting cyclooxygenase</li>
<li>effect: analgesia &amp; antipyresis</li>
</ul>
<h2 id="How-drugs-act"><a href="#How-drugs-act" class="headerlink" title="How drugs act"></a>How drugs act</h2><p>Many drugs exert their actions by binding to protein targets on mammalian cells</p>
<ul>
<li>Receptors </li>
<li>Ion channels </li>
<li>Enzymes </li>
<li>Carrier molecules</li>
</ul>
<p>Exceptions</p>
<ul>
<li>Antibiotics (protein, DNA or lipid membrane)</li>
<li>Anti-cancer drugs (similar to above)</li>
<li>Etc.</li>
</ul>
<h2 id="Drug-and-Receptor-Interaction"><a href="#Drug-and-Receptor-Interaction" class="headerlink" title="Drug and Receptor Interaction"></a>Drug and Receptor Interaction</h2><p>primary way drugs produce an action</p>
<ul>
<li><p>RECEPTOR</p>
<ul>
<li>The component of a cell or organism that interacts with a drug and initiates the chain of events leading to the drug’s observed effects</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202626609.png" srcset="/img/loading.gif" lazyload alt="image-20210315202626609" style="zoom:100%;" /></li>
</ul>
<h2 id="Receptor-Types"><a href="#Receptor-Types" class="headerlink" title="Receptor Types"></a>Receptor Types</h2><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202659615.png" srcset="/img/loading.gif" lazyload alt="image-20210315202659615" style="zoom:100%;" />

<h3 id="1-Intracellular-Receptors-for-Lipid-Soluble-Agents"><a href="#1-Intracellular-Receptors-for-Lipid-Soluble-Agents" class="headerlink" title="1. Intracellular Receptors for Lipid-Soluble Agents"></a>1. Intracellular Receptors for Lipid-Soluble Agents</h3><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202826694.png" srcset="/img/loading.gif" lazyload alt="image-20210315202826694" style="zoom:100%;" />

<ul>
<li>Several biologic signals are sufficiently lipid-soluble to cross the plasma membrane and act on intracellular receptors.</li>
<li>The ligands include steroids, sex steroids, vitamin D, and thyroid hormone</li>
</ul>
<p><strong>Therapeutical consequences of intracellular receptors</strong></p>
<ul>
<li>transcription and translation take about 30 min</li>
<li>All of these hormones (ligands) produce their effects after a period of 30 minutes to several hours</li>
<li>The effects of these agents can persist for hours or days after the agonist concentration has been reduced to zero</li>
</ul>
<h3 id="2-Ligand-Gated-Channels"><a href="#2-Ligand-Gated-Channels" class="headerlink" title="2. Ligand-Gated Channels"></a>2. Ligand-Gated Channels</h3><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315202959083.png" srcset="/img/loading.gif" lazyload alt="image-20210315202959083" style="zoom: 50%;" />

<p>The open of channel results in the flow of ion and thereby alters the electrical potential across the membrane</p>
<ul>
<li>The natural ligands including N-acetylcholine, excitatory amino acids (glycine, glutamate, etc), γ-GABA (Cl-, chlorine).</li>
<li>All of these agents are synaptic transmitters</li>
</ul>
<p>The time scale of signaling is about milliseconds</p>
<p>The rapidity of this signaling is crucially important for moment transfer of information across synapses</p>
<h3 id="3-G-protein-coupled-Receptors"><a href="#3-G-protein-coupled-Receptors" class="headerlink" title="3. G-protein-coupled Receptors"></a>3. G-protein-coupled Receptors</h3><p>This is the largest receptors family with over a hundred members cloned to date</p>
<p>G-protein: a kind of GTP-binding proteins with subunit of αβγ</p>
<p>Characteristics: seven-times crossing the plasma membrane, use G protein as transducers to convey signal to their effector proteins</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203134943.png" srcset="/img/loading.gif" lazyload alt="image-20210315203134943" style="zoom:100%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203257458.png" srcset="/img/loading.gif" lazyload alt="image-20210315203257458" style="zoom:100%;" />

<p>Members: include receptors for many biogenic amines, such as adrenalin, DA, histamine, M-acetylcholine, and others.</p>
<p>G-protein-regulated effectors include enzymes such as <strong>adenylyl cyclase</strong> and phospholipase C and plasma membrane ion channels.</p>
<h4 id="Well-Established-Second-Messengers"><a href="#Well-Established-Second-Messengers" class="headerlink" title="Well-Established Second Messengers"></a>Well-Established Second Messengers</h4><p>metabolite or ion that diffuse through a cell to convey information</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203332282.png" srcset="/img/loading.gif" lazyload alt="image-20210315203332282" style="zoom:100%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203340234.png" srcset="/img/loading.gif" lazyload alt="image-20210315203340234" style="zoom:100%;" />

<p>Is synthesized by adenylyl cyclase under the control of many G protein-coupled receptors</p>
<p>Is eliminated by a combination of hydrolysis, catalyzed by phosphodiesterases, and extrusion by several plasma membrane transport proteins</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315203730998.png" srcset="/img/loading.gif" lazyload alt="image-20210315203730998" style="zoom:100%;" />

<ul>
<li>Activate <strong>cyclic AMP-dependent protein kinases</strong> (PKA)</li>
<li>The <strong>PKA</strong> can phosphorylate both final physiological targets and numerous protein kinases and other regulatory proteins, Including transcription factors to regulate gene expression</li>
</ul>
<h4 id="Cyclic-AMP"><a href="#Cyclic-AMP" class="headerlink" title="Cyclic AMP"></a>Cyclic AMP</h4><p>These kinases are composed of a cAMP-binding domain and catalytic chains</p>
<p>The <strong>PKA</strong> can phosphorylate both final physiological targets and numerous protein kinases and other regulatory proteins, including transcription factors</p>
<ul>
<li>Regulate gene expression</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315204050913.png" srcset="/img/loading.gif" lazyload alt="image-20210315204050913" style="zoom:100%;" />

<h4 id="Calcium-and-Phosphoinositides"><a href="#Calcium-and-Phosphoinositides" class="headerlink" title="Calcium and Phosphoinositides"></a>Calcium and Phosphoinositides</h4><p>Phospholipase C splits the phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol-1,4,5trisphosphate (IP3)</p>
<ul>
<li>DAG is confined to the membrane and activates a phospholipid and calcium-sensitive protein kinase called <strong>protein kinase C.</strong></li>
<li>IP3 triggers release of Ca2+ from internal storage vesicles</li>
</ul>
<h3 id="4-Ligand-Regulated-Transmembrane-Enzymes-Including-Receptor-Tyrosine-Kinases"><a href="#4-Ligand-Regulated-Transmembrane-Enzymes-Including-Receptor-Tyrosine-Kinases" class="headerlink" title="4. Ligand-Regulated Transmembrane Enzymes Including Receptor Tyrosine Kinases"></a>4. Ligand-Regulated Transmembrane Enzymes Including Receptor Tyrosine Kinases</h3><p>Be composed of an extracelluar ligand-binding domain and a cytoplasmic enzyme domain (protein tyrosine&#x2F;serine (threonine) kinase or a guanylyl cyclase)</p>
<p>Insulin, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and many other trophic hormones.</p>
<p>Ligand bind, conformation change, receptors bind to one another, tyrosine residues cross-phosphorylated</p>
<p>Activated receptors catalyze phosphorylation of tyrosine residues in their substrates</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315204328898.png" srcset="/img/loading.gif" lazyload alt="image-20210315204328898" style="zoom:100%;" />

<h4 id="Therapeutical-consequences"><a href="#Therapeutical-consequences" class="headerlink" title="Therapeutical consequences"></a>Therapeutical consequences</h4><p>Inhibitors of receptor tyrosine kinases are finding increased use in neoplastic disorders</p>
<p>Ligand binding often induces accelerated endocytosis of receptors from the cell surface and degradation (down-regulation)</p>
<h2 id="Theory-and-assumptions-of-drug-receptor-interaction"><a href="#Theory-and-assumptions-of-drug-receptor-interaction" class="headerlink" title="Theory and assumptions of drug-receptor interaction"></a>Theory and assumptions of drug-receptor interaction</h2><p>Binding to receptor causes some event which leads to the response.</p>
<p>Response to a drug is graded or dose-dependent.</p>
<p>For a given drug, the magnitude of response is directly proportional to the fraction of total receptor sites occupied by drug molecules (i.e. the occupancy assumption).</p>
<p>The number of drug molecules is assumed to be much greater than the number of receptor sites.</p>
<p>Binding of drug with a receptor produces a specific response. “lock and key”.</p>
<p>Drug-receptor interactions are analogous to enzyme-substrate interactions.</p>
<ul>
<li>Endogenous ligands (e.g. enkephalin versus morphine).</li>
<li>Drugs without specific receptors (e.g. gaseous anesthetics).</li>
</ul>
<h1 id="Drug-and-receptor-interaction"><a href="#Drug-and-receptor-interaction" class="headerlink" title="Drug and receptor interaction"></a>Drug and receptor interaction</h1><p>Drug receptor interaction follows simple mass-action relationships, i.e., only one drug molecule occupies each receptor site and binding is reversible. Can be described with <strong>Michaelis Menten equation</strong>:</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315204857526.png" srcset="/img/loading.gif" lazyload alt="image-20210315204857526" style="zoom: 50%;" />

<p>When a drug (D) combines with a receptor (R), it does so at a rate which is dependent on the concentration of the drug and the concentration of the receptor</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205123930.png" srcset="/img/loading.gif" lazyload alt="image-20210315205123930" style="zoom: 67%;" />

<p>D &#x3D; drug</p>
<p>R &#x3D; receptor,</p>
<p>DR &#x3D; drug-receptor complex</p>
<p>k1 &#x3D; rate for association</p>
<p>k2 &#x3D; rate for dissociation.</p>
<p>KD &#x3D; Dissociation Constant</p>
<p>KA &#x3D; Association Constant</p>
<h2 id="Saturation-curve"><a href="#Saturation-curve" class="headerlink" title="Saturation curve"></a>Saturation curve</h2><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205156808.png" srcset="/img/loading.gif" lazyload alt="image-20210315205156808" style="zoom: 50%;" />

<p>A. Total binding<br>B. Nonspecific binding<br>C. Difference&#x3D;Specific binding</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205257899.png" srcset="/img/loading.gif" lazyload alt="image-20210315205257899" style="zoom:100%;" />

<p>RT&#x3D; Total number of receptors</p>
<p>Bmax &#x3D; Maximal number of receptors Bound</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205318537.png" srcset="/img/loading.gif" lazyload alt="image-20210315205318537" style="zoom:100%;" />

<p>At equilibrium, the dissociation constant is KD and the affinity is KA&#x3D; 1&#x2F;KD Thus when [D] &#x3D;KD, half the total number of receptors will be occupied.</p>
<h2 id="Terminology"><a href="#Terminology" class="headerlink" title="Terminology"></a>Terminology</h2><p>Terms which indicate ability of drug to bind to receptor</p>
<ul>
<li>Potency</li>
<li>Affinity (1&#x2F;KD)</li>
<li>KD or ED50 (Effective dose 50)</li>
<li>(Corresponds to Km in Michaelis-Menten analogy)</li>
</ul>
<h2 id="Concentration-Bound-Receptors"><a href="#Concentration-Bound-Receptors" class="headerlink" title="Concentration-Bound Receptors"></a>Concentration-Bound Receptors</h2><p>Bmax indicates the total concentration of receptor sites</p>
<p>KD represents the concentration of free drug at which half-maximal binding is observed</p>
<p>This constant characterizes the receptor’s affinity for binding the drug in a reciprocal fashion</p>
<p>The EC50 and Kd may be identical, but need not be</p>
<h2 id="Relation-Between-Drug-Concentration-and-Response"><a href="#Relation-Between-Drug-Concentration-and-Response" class="headerlink" title="Relation Between Drug Concentration and Response"></a>Relation Between Drug Concentration and Response</h2><p>D-E relationship of patient</p>
<p>C-E relationship of in vitro system</p>
<p><strong>Concentration-Effect Curves &amp; Receptor Binding of Agonists</strong></p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205620730.png" srcset="/img/loading.gif" lazyload alt="image-20210315205620730" style="zoom:100%;" />

<p><strong>Concentration-Effect Curves</strong></p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315205641227.png" srcset="/img/loading.gif" lazyload alt="image-20210315205641227" style="zoom:100%;" />

<ul>
<li>If plotted the E versus log D or log C, the curve become typical symmetrical sigmoid curve.</li>
<li>Expands the low and compresses high concentration</li>
</ul>
<h2 id="Classification-of-Drugs-based-on-PD"><a href="#Classification-of-Drugs-based-on-PD" class="headerlink" title="Classification of Drugs based on PD"></a>Classification of Drugs based on PD</h2><p><strong>Antagonist</strong></p>
<ul>
<li>A pure antagonist, which can bind to receptors without efficacy, antagonizes the biologic effects of the corresponding agonist.</li>
<li>Competitive &amp; Irreversible Antagonists<ul>
<li>Antagonists are divided into two classes depending on whether or not they reversibly compete with agonists for binding to receptors</li>
<li>Competitive antagonist</li>
<li>Noncompetitive&#x2F;irreversible antagonist</li>
<li><strong>Competitive antagonist</strong><ul>
<li>Competes the same receptor with agonist and reversibly binds to receptors</li>
<li>The Emax for the agonist remains the same for any fixed concentration of antagonist</li>
<li>The presence of antagonist will increase the ED50 of the agonist</li>
<li>So the D-E curve of agonist will shift to the right</li>
<li><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315214914472.png" srcset="/img/loading.gif" lazyload alt="image-20210315214914472" style="zoom:100%;" /></li>
<li><strong>Therapeutic Implications</strong><ul>
<li>The degree of inhibition produced by a competitive antagonist depends on the concentration of antagonist. D→C</li>
<li>Clinical response to a competitive antagonist depends on the concentration of agonist that is competing for binding to receptors</li>
</ul>
</li>
</ul>
</li>
<li><strong>Non-competitive antagonist</strong><ul>
<li>Irreversibly binds to receptors</li>
<li>The antagonism can not be overcome by increasing the concentration of the agonist, that is to say the maximal effects of the agonist are depressed by the corresponding noncompetitive antagonist</li>
<li>make the height of the curve descend.</li>
<li><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315215630602.png" srcset="/img/loading.gif" lazyload alt="image-20210315215630602" style="zoom:100%;" /></li>
<li><strong>Therapeutic Implications</strong><ul>
<li>Therapeutically, irreversible antagonists present distinctive advantages and disadvantages</li>
<li>Consequently, the duration of action of such an irreversible antagonist is relatively independent of its own rate of elimination and more dependent on the rate of turnover of receptor molecules</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><strong>Agonist</strong></p>
<ul>
<li><p>Can bind to receptors, then activate receptors and produce pharmacological effect.</p>
</li>
<li><p>Agonist I drugs (direct agonists)</p>
<ul>
<li>bind to same site as endogenous ligand</li>
<li>effect? similar to ligand</li>
</ul>
</li>
<li><p>Agonist II drugs (indirect agonists)</p>
<ul>
<li>bind to different cell site<ul>
<li>do not produce effect themselves</li>
<li>enhance effect of natural ligand</li>
</ul>
</li>
</ul>
</li>
<li><p><strong>Partial Agonists</strong></p>
</li>
<li><p>Based on the maximal pharmacologic response that occurs when all receptors are occupied, agonist can be divided into two classes:</p>
<ul>
<li>Partial agonists produce a lower response, at full receptor occupancy, than do full agonists</li>
<li>The effects of full agonists can be considered more efficiently coupled to receptor occupancy than can the effects of partial agonists<ul>
<li>Partial agonists produce C-E curves that resemble those observed with full agonists in the presence of irreversible antagonists</li>
<li>The failure of partial agonists to produce a maximal response is not due to decreased affinity for binding to receptors <u>(low intrinsic activity)</u></li>
<li>Partial agonists competitively inhibit the responses produced by full agonists</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="Dose-effect-Relationship"><a href="#Dose-effect-Relationship" class="headerlink" title="Dose-effect Relationship"></a>Dose-effect Relationship</h2><p>In a certain range of doses, the pharmacological response is increased in proportion with the increase in doses.</p>
<h2 id="Dose-response-curve"><a href="#Dose-response-curve" class="headerlink" title="Dose-response curve"></a>Dose-response curve</h2><p>The dose-effect curve can be obtained from plotting the pharmacological effect intension (E) as y axis versus dosage (D) or concentration (C) of drugs as x axis</p>
<h2 id="Dose-Response-in-Patients"><a href="#Dose-Response-in-Patients" class="headerlink" title="Dose &amp; Response in Patients"></a>Dose &amp; Response in Patients</h2><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315220126347.png" srcset="/img/loading.gif" lazyload alt="image-20210315220126347" />

<h3 id="1-Graded-response"><a href="#1-Graded-response" class="headerlink" title="1. Graded response"></a>1. Graded response</h3><p>In a certain range of doses, the pharmacological response increases with the increasing of doses.</p>
<p>blood pressure, muscle contraction, urinary excretion of sodium</p>
<h3 id="2-Quantal-response-or-all-or-none-response"><a href="#2-Quantal-response-or-all-or-none-response" class="headerlink" title="2. Quantal response or all-or-none response"></a>2. Quantal response or all-or-none response</h3><p>Indicate that a given dose of a drug has or has not evoked a certain effect in the various subjects under investigation.</p>
<p>Expressed with all or none, positive or negative, e.g., death or survival, convulsion or not, paralysis or not</p>
<h2 id="Potency"><a href="#Potency" class="headerlink" title="Potency"></a>Potency</h2><p>Refers to the concentration (EC50) or dose (ED50) of a drug required to produce 50% of that drug’s maximal effect.</p>
<ul>
<li>What is mean more potent?<ul>
<li>Nitroglycerin is very potent; relatively few molecules need to absorbed to produce the therapeutic effect</li>
</ul>
</li>
<li>If the drug is to be administered by transdermal absorption, a highly potent drug is required, since the capacity of the skin to absorb drugs is limited</li>
</ul>
<p>SEMILOG DOSE-RESPONSE CURVE</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315220248986.png" srcset="/img/loading.gif" lazyload alt="image-20210315220248986" style="zoom:100%;" />

<h2 id="Maximal-Efficacy"><a href="#Maximal-Efficacy" class="headerlink" title="Maximal Efficacy"></a>Maximal Efficacy</h2><p>The maximal effect that can be produced by a drug is its maximal efficacy. It reflects the limit of the dose-response relation on the response axis</p>
<p>The maximal efficacy of a drug for achieving a therapeutic end point may be limited by the drug’s propensity to cause a toxic effect even if the drug could otherwise produce a greater therapeutic effect</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315220309971.png" srcset="/img/loading.gif" lazyload alt="image-20210315220309971" style="zoom:100%;" />

<h2 id="Median-effect-dose-ED50"><a href="#Median-effect-dose-ED50" class="headerlink" title="Median effect dose (ED50)"></a>Median effect dose (ED50)</h2><p>For all-or-none responses, the dose of a drug that gives rise to a response in 50% of the subjects is called ED50</p>
<p>It provide a convenient way of comparing the potencies of drugs in experimental and clinical settings</p>
<h3 id="1-Meanings-of-ED50"><a href="#1-Meanings-of-ED50" class="headerlink" title="1. Meanings of ED50"></a>1. Meanings of ED50</h3><p>If the ED50s of two drugs for producing a specified quantal effect are 5 and 500 mg, respectively, then：</p>
<ul>
<li>One can obtain a valuable index of the selectivity of a drug’s action by comparing its ED50s for two different quantal effects in a population</li>
<li>Eg, cough suppression versus sedation for opioid drugs</li>
</ul>
<h2 id="Median-lethal-dose-LD50"><a href="#Median-lethal-dose-LD50" class="headerlink" title="Median lethal dose (LD50)"></a>Median lethal dose (LD50)</h2><p>A dose that gives rise to the death of 50% of subjects is called LD50</p>
<p>LD50 is a primary index evaluated the safety of a drug, but it can not reflect the relationship between drug effect and toxic effect.</p>
<h2 id="Therapeutic-index-TI"><a href="#Therapeutic-index-TI" class="headerlink" title="Therapeutic index (TI)"></a>Therapeutic index (TI)</h2><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210315221048117.png" srcset="/img/loading.gif" lazyload alt="image-20210315221048117" style="zoom:100%;" />

<p>Is a measure which relates the dose of a drug required to produce a desired effect to that which produces an undesired effect -denotes the safety of the drugs</p>
<p>TI&#x3D;LD50&#x2F;ED50 （LC50&#x2F;EC50）</p>
<ul>
<li>The larger value of the TI is, the wider margin between effective dose and toxic dose is. For example, the drug of TI&#x3D;4 is more safe than that of TI&#x3D;2.</li>
</ul>

                
              </div>
            
            <hr/>
            <div>
              <div class="post-metas my-3">
  
    <div class="post-meta mr-3 d-flex align-items-center">
      <i class="iconfont icon-category"></i>
      

<span class="category-chains">
  
  
    
      <span class="category-chain">
        
  <a href="/categories/Academic-Notebook/" class="category-chain-item">Academic Notebook</a>
  
  
    <span>></span>
    
  <a href="/categories/Academic-Notebook/Molecular-Pharmacology/" class="category-chain-item">Molecular Pharmacology</a>
  
  

  

      </span>
    
  
</span>

    </div>
  
  
    <div class="post-meta">
      <i class="iconfont icon-tags"></i>
      
        <a href="/tags/Molecular-Pharmacology/" class="print-no-link">#Molecular Pharmacology</a>
      
    </div>
  
</div>


              
  

  <div class="license-box my-3">
    <div class="license-title">
      <div>L4 Drug Receptors &amp; Pharmacodynamics</div>
      <div>https://zhenyumi.github.io/posts/c9f809bd/</div>
    </div>
    <div class="license-meta">
      
        <div class="license-meta-item">
          <div>作者</div>
          <div>向海</div>
        </div>
      
      
        <div class="license-meta-item license-meta-date">
          <div>发布于</div>
          <div>2021年4月16日</div>
        </div>
      
      
      
        <div class="license-meta-item">
          <div>许可协议</div>
          <div>
            
              
              
                <a class="print-no-link" target="_blank" href="https://creativecommons.org/licenses/by/4.0/">
                  <span class="hint--top hint--rounded" aria-label="BY - 署名">
                    <i class="iconfont icon-cc-by"></i>
                  </span>
                </a>
              
            
          </div>
        </div>
      
    </div>
    <div class="license-icon iconfont"></div>
  </div>



              
                <div class="post-prevnext my-3">
                  <article class="post-prev col-6">
                    
                    
                      <a href="/posts/aec0f5de/" title="L5 Autonomic pharmacology: cholinergic and anti cholinergic drugs">
                        <i class="iconfont icon-arrowleft"></i>
                        <span class="hidden-mobile">L5 Autonomic pharmacology: cholinergic and anti cholinergic drugs</span>
                        <span class="visible-mobile">上一篇</span>
                      </a>
                    
                  </article>
                  <article class="post-next col-6">
                    
                    
                      <a href="/posts/434f152/" title="L3 Pharmacokinetics">
                        <span class="hidden-mobile">L3 Pharmacokinetics</span>
                        <span class="visible-mobile">下一篇</span>
                        <i class="iconfont icon-arrowright"></i>
                      </a>
                    
                  </article>
                </div>
              
            </div>

            
          </article>
        </div>
      </div>
    </div>

    <div class="side-col d-none d-lg-block col-lg-2">
      
  <aside class="sidebar" style="margin-left: -1rem">
    <div id="toc">
  <p class="toc-header">
    <i class="iconfont icon-list"></i>
    <span>目录</span>
  </p>
  <div class="toc-body" id="toc-body"></div>
</div>



  </aside>


    </div>
  </div>
</div>





  



  



  



  



  


  
  









    

    
      <a id="scroll-top-button" aria-label="TOP" href="#" role="button">
        <i class="iconfont icon-arrowup" aria-hidden="true"></i>
      </a>
    

    
      <div class="modal fade" id="modalSearch" tabindex="-1" role="dialog" aria-labelledby="ModalLabel"
     aria-hidden="true">
  <div class="modal-dialog modal-dialog-scrollable modal-lg" role="document">
    <div class="modal-content">
      <div class="modal-header text-center">
        <h4 class="modal-title w-100 font-weight-bold">搜索</h4>
        <button type="button" id="local-search-close" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body mx-3">
        <div class="md-form mb-5">
          <input type="text" id="local-search-input" class="form-control validate">
          <label data-error="x" data-success="v" for="local-search-input">关键词</label>
        </div>
        <div class="list-group" id="local-search-result"></div>
      </div>
    </div>
  </div>
</div>

    

    
  </main>

  <footer>
    <div class="footer-inner">
  
    <div class="footer-content">
       <a href="https://hexo.io" target="_blank" rel="nofollow noopener"><span>Hexo</span></a> <i class="iconfont icon-love"></i> <a href="https://github.com/fluid-dev/hexo-theme-fluid" target="_blank" rel="nofollow noopener"><span>Fluid</span></a> 
    </div>
  
  
  
</div>

  </footer>

  <!-- Scripts -->
  
  <script  src="https://lib.baomitu.com/nprogress/0.2.0/nprogress.min.js" ></script>
  <link  rel="stylesheet" href="https://lib.baomitu.com/nprogress/0.2.0/nprogress.min.css" />

  <script>
    NProgress.configure({"showSpinner":false,"trickleSpeed":100})
    NProgress.start()
    window.addEventListener('load', function() {
      NProgress.done();
    })
  </script>


<script  src="https://lib.baomitu.com/jquery/3.6.4/jquery.min.js" ></script>
<script  src="https://lib.baomitu.com/twitter-bootstrap/4.6.1/js/bootstrap.min.js" ></script>
<script  src="/js/events.js" ></script>
<script  src="/js/plugins.js" ></script>





  
    <script  src="/js/img-lazyload.js" ></script>
  




  
<script>
  Fluid.utils.createScript('https://lib.baomitu.com/tocbot/4.20.1/tocbot.min.js', function() {
    var toc = jQuery('#toc');
    if (toc.length === 0 || !window.tocbot) { return; }
    var boardCtn = jQuery('#board-ctn');
    var boardTop = boardCtn.offset().top;

    window.tocbot.init(Object.assign({
      tocSelector     : '#toc-body',
      contentSelector : '.markdown-body',
      linkClass       : 'tocbot-link',
      activeLinkClass : 'tocbot-active-link',
      listClass       : 'tocbot-list',
      isCollapsedClass: 'tocbot-is-collapsed',
      collapsibleClass: 'tocbot-is-collapsible',
      scrollSmooth    : true,
      includeTitleTags: true,
      headingsOffset  : -boardTop,
    }, CONFIG.toc));
    if (toc.find('.toc-list-item').length > 0) {
      toc.css('visibility', 'visible');
    }

    Fluid.events.registerRefreshCallback(function() {
      if ('tocbot' in window) {
        tocbot.refresh();
        var toc = jQuery('#toc');
        if (toc.length === 0 || !tocbot) {
          return;
        }
        if (toc.find('.toc-list-item').length > 0) {
          toc.css('visibility', 'visible');
        }
      }
    });
  });
</script>


  <script src=https://lib.baomitu.com/clipboard.js/2.0.11/clipboard.min.js></script>

  <script>Fluid.plugins.codeWidget();</script>


  
<script>
  Fluid.utils.createScript('https://lib.baomitu.com/anchor-js/5.0.0/anchor.min.js', function() {
    window.anchors.options = {
      placement: CONFIG.anchorjs.placement,
      visible  : CONFIG.anchorjs.visible
    };
    if (CONFIG.anchorjs.icon) {
      window.anchors.options.icon = CONFIG.anchorjs.icon;
    }
    var el = (CONFIG.anchorjs.element || 'h1,h2,h3,h4,h5,h6').split(',');
    var res = [];
    for (var item of el) {
      res.push('.markdown-body > ' + item.trim());
    }
    if (CONFIG.anchorjs.placement === 'left') {
      window.anchors.options.class = 'anchorjs-link-left';
    }
    window.anchors.add(res.join(', '));

    Fluid.events.registerRefreshCallback(function() {
      if ('anchors' in window) {
        anchors.removeAll();
        var el = (CONFIG.anchorjs.element || 'h1,h2,h3,h4,h5,h6').split(',');
        var res = [];
        for (var item of el) {
          res.push('.markdown-body > ' + item.trim());
        }
        if (CONFIG.anchorjs.placement === 'left') {
          anchors.options.class = 'anchorjs-link-left';
        }
        anchors.add(res.join(', '));
      }
    });
  });
</script>


  
<script>
  Fluid.utils.createScript('https://lib.baomitu.com/fancybox/3.5.7/jquery.fancybox.min.js', function() {
    Fluid.plugins.fancyBox();
  });
</script>


  <script>Fluid.plugins.imageCaption();</script>

  
      <script>
        if (!window.MathJax) {
          window.MathJax = {
            tex    : {
              inlineMath: { '[+]': [['$', '$']] }
            },
            loader : {
              load: ['ui/lazy']
            },
            options: {
              renderActions: {
                insertedScript: [200, () => {
                  document.querySelectorAll('mjx-container').forEach(node => {
                    let target = node.parentNode;
                    if (target.nodeName.toLowerCase() === 'li') {
                      target.parentNode.classList.add('has-jax');
                    }
                  });
                }, '', false]
              }
            }
          };
        } else {
          MathJax.startup.document.state(0);
          MathJax.texReset();
          MathJax.typeset();
          MathJax.typesetPromise();
        }

        Fluid.events.registerRefreshCallback(function() {
          if ('MathJax' in window && MathJax.startup.document && typeof MathJax.startup.document.state === 'function') {
            MathJax.startup.document.state(0);
            MathJax.texReset();
            MathJax.typeset();
            MathJax.typesetPromise();
          }
        });
      </script>
    

  <script  src="https://lib.baomitu.com/mathjax/3.2.2/es5/tex-mml-chtml.js" ></script>

  <script  src="/js/local-search.js" ></script>





<!-- 主题的启动项，将它保持在最底部 -->
<!-- the boot of the theme, keep it at the bottom -->
<script  src="/js/boot.js" ></script>


  

  <noscript>
    <div class="noscript-warning">博客在允许 JavaScript 运行的环境下浏览效果更佳</div>
  </noscript>
</body>
</html>
